Everybody is talking bispecific antibodies - they hold the promise of being next generation of blockbusting biologics. The industry’s focus on bispecifics is intensifying: they have been the subject of several impressive deals worth more than $3.5 billion in the past 2 years.
There are exciting opportunities to embrace and huge scope for growth. But there are still many issues that need to be addressed before this new class of drug can reach its full potential.
Whether you have a candidate entering the clinic, you’re working on a tech platform or if your company is developing a strategy to move into this space. Here is your chance to learn from others who are as enthusiastic about bispecifics as you.
The World Bispecific Antibody Summit is the world’s first meeting dedicated to advancing the understanding of bispecifics.
You have told us what you want to learn and the challenges you need to address. We’ve turned this into an essential program.
• Explore the different potential applications for bispecifics
• Develop robust rationales for target selection
• See case study examples of flexible platforms that can be used to develop bispecifics for a number of different targets
• Get guidance on clinical trial design, regulatory requirements and the criteria for success of a bispecific candidate from those who have already entered the clinic
• Formulate strategies for avoiding immunogenicity
• Learn about the latest advancements in non-antibody scaffolds
• Discover methods of improving the solubility, stability and half-life of a bispecific molecule
• Improve your candidates’ expression, and streamline your upstream and downstream processing

Enter code AC5 on registration for a 5% discount.